RT Journal Article
SR Electronic
T1 High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients
JF Life Science Alliance
JO Life Sci. Alliance
FD Life Science Alliance LLC
SP e202001009
DO 10.26508/lsa.202001009
VO 4
IS 9
A1 Rodríguez de la Concepción, María Luisa
A1 Ainsua-Enrich, Erola
A1 Reynaga, Esteban
A1 Ávila-Nieto, Carlos
A1 Santos, Jose Ramón
A1 Roure, Silvia
A1 Mateu, Lourdes
A1 Paredes, Roger
A1 Puig, Jordi
A1 Jimenez, Juan Manuel
A1 Izquierdo-Useros, Nuria
A1 Clotet, Bonaventura
A1 Pedro-Botet, María Luisa
A1 Carrillo, Jorge
YR 2021
UL http://www.life-science-alliance.org/content/4/9/e202001009.abstract
AB The use of high-dose of intravenous immunoglobulins (IVIGs) as immunomodulators for the treatment of COVID-19–affected individuals has shown promising results. IVIG reduced inflammation in these patients, who progressively restored respiratory function. However, little is known about how they may modulate immune responses in COVID-19 individuals. Here, we have analyzed the levels of 41 inflammatory biomarkers in plasma samples obtained at day 0 (pretreatment initiation), 3, 7, and 14 from five hospitalized COVID-19 patients treated with a 5-d course of 400 mg/kg/d of IVIG. The plasmatic levels of several cytokines (Tumor Necrosis Factor, IL-10, IL-5, and IL-7), chemokines (macrophage inflammatory protein-1α), growth/tissue repairing factors (hepatic growth factor), complement activation (C5a), and intestinal damage such as Fatty acid–binding protein 2 and LPS-binding protein showed a progressive decreasing trend during the next 2 wk after treatment initiation. This trend was not observed in IVIG-untreated COVID-19 patients. Thus, the administration of high-dose IVIG to hospitalized COVID-19 patients may improve their clinical evolution by modulating their hyperinflammatory and immunosuppressive status.